Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, et al.
Metabolism (2024) Vol. 154, pp. 155835-155835
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 27
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 17
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 14
Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
Mohamed El‐Kassas, Hala Mostafa, Wessam Abdellatif, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 2
Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world
Li-You Lian, Giovanni Targher, Christopher D. Byrne, et al.
Metabolism (2024) Vol. 156, pp. 155935-155935
Closed Access | Times Cited: 11
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management
Stergios A. Pοlyzos, Christos S. Mantzoros
Metabolism (2024) Vol. 157, pp. 155936-155936
Closed Access | Times Cited: 9
Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review
Shihao Zheng, Chengyuan Xue, Size Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 7
Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution
Wenjie Yu, Yu Zhang, Linfeng Sun, et al.
Metabolism (2024) Vol. 155, pp. 155911-155911
Open Access | Times Cited: 6
The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis
María Mercado-Gómez, Naroa Goikoetxea‐Usandizaga, Annarein Kerbert, et al.
Metabolism (2024) Vol. 158, pp. 155952-155952
Closed Access | Times Cited: 6
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility
Sara Paola Mambrini, Antônio Grillo, Santo Colosimo, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 6
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 5
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
Xiang Zhang, Harry Cheuk-Hay Lau, Jun Yu
Pharmacological Reviews (2025) Vol. 77, Iss. 2, pp. 100018-100018
Open Access
Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome”
Suleiman Al Ashi, Ali A. Rizvi, Manfredi Rizzo
Frontiers in Clinical Diabetes and Healthcare (2025) Vol. 5
Open Access
New drug therapies for metabolic dysfunction-associated steatohepatitis
John Y.L. Chiang
Liver Research (2025)
Open Access
Caffeine Ameliorates Metabolic-Associated Steatohepatitis by Rescuing Hepatic Dusp9
Xin Xin, Cheng Chen, Xiaoxue Xu, et al.
Redox Biology (2025) Vol. 80, pp. 103499-103499
Open Access
Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis
Qingqing Dai, Quratul Ain, Namdev Seth, et al.
Digestive and Liver Disease (2025)
Open Access
An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis
Keying Jiang, Jianfeng Bao, Zhonghan Lou, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 227-227
Open Access
Advances in Nanotechnology for the Diagnosis and Management of Metabolic Dysfunction-associated Steatotic Liver Disease
Fenfen Li, Ruyan Yuan, Jiamin Zhang, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101025-101025
Open Access
Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
Mohamed Toufic El Hussein, Daniel Favell
The Journal for Nurse Practitioners (2025) Vol. 21, Iss. 2, pp. 105273-105273
Closed Access
Computational modelling in liver system and liver disease
Yunjie Liao, Nathan Davies, I. David L. Bogle
Physical Sciences Reviews (2025)
Closed Access
Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease
Lihui Zhang, Sutong Liu, Qing Zhao, et al.
World Journal of Hepatology (2025) Vol. 17, Iss. 2
Closed Access
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis, Maria Chondrogianni, Θεόδωρος Ανδρουτσάκος, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 324-324
Open Access
Page 1 - Next Page

Scroll to top